Li Philip K T, Chow K M, Szeto C C
Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.
Int J Artif Organs. 2003 May;26(5):363-72. doi: 10.1177/039139880302600501.
Over the last decade, epidemiological surveys and qualitative research literature have demonstrated and validated a better survival in the Asian peritoneal dialysis population. This review summarizes the current understanding of Asian peritoneal dialysis patient survival and attempts to scrutinize the supposed survival advantage of this population group. We outlined the published peritoneal dialysis survival data from a literature search, with reference to dialysis patient cohorts from 1983 through 2002 for prevalent cases and 1980 through 2002 for incident patients. Two-year and 5-year patient survival rates in excess of 80% and 60% respectively were demonstrated in Asian countries, which compared favorably with the CANUSA, ADEMEX and most Caucasian series. Better end-stage renal disease patient survival is apparent despite a dialysis adequacy disadvantage, for reasons yet to be identified. As is the case of other racial disparities in medical care, such a difference is a product of more than biological differences and include budgetary barrier, health care system and geographic variation, physician bias and statistical pitfalls. Particular efforts should therefore be made to explore the underlying reason(s) for the Asian peritoneal dialysis patient survival advantage. Alternative approach and guidelines to peritoneal dialysis delivery in Asia might be warranted.
在过去十年中,流行病学调查和定性研究文献已证明并验证了亚洲腹膜透析人群有更好的生存率。本综述总结了目前对亚洲腹膜透析患者生存率的认识,并试图仔细研究该人群所谓的生存优势。我们通过文献检索列出了已发表的腹膜透析生存数据,参考了1983年至2002年的透析患者队列以获取现患病例数据,以及1980年至2002年的透析患者队列以获取新发病例数据。亚洲国家的患者两年和五年生存率分别超过80%和60%,与加拿大-美国(CANUSA)、墨西哥腹膜透析协作研究(ADEMEX)以及大多数白种人系列研究相比具有优势。尽管透析充分性存在劣势,但终末期肾病患者的生存率更高,原因尚待确定。与医疗保健中其他种族差异的情况一样,这种差异不仅仅是生物学差异的产物,还包括预算障碍、医疗保健系统和地理差异、医生偏见以及统计陷阱。因此,应特别努力探索亚洲腹膜透析患者生存优势的潜在原因。或许有必要采用其他方法和指南来进行亚洲的腹膜透析治疗。